Patent law
Sir-In response to Amir Attaran's criticisms of our report (Feb 15, p 613) , 1 we think that Attaran raises important issues, but our interpretation of most of them is different.
Attaran's first point is that patents apply to individual products not to a class, so they do not automatically create a monopoly. In theory yes, but in practice no. Implementation of the patent system in a situation characterised by market failure has contributed to poor access to many drugs, even in developed countries. True price competition is absent between patented products of the same class, which effectively puts whole classes of new drugs out of reach of many countries that do not provide drug coverage.
The point we were trying to make with esomeprazole is that (effectively) it is omeprazole. It is the S-isomer. This case is a classic example of evergreening. In our view, esomeprazole's development as a socalled new product is an exercise in marketing, not science, which is only possible with the current patent system and in the presence of market failure. Development of this drug means that large amounts of money were spent with no prospect of great medical progress. Patents are being used to exploit the rather naive belief of doctors, consumers, and the media in the value of new drugs.
Attaran's third point is the muchdebated issue of in-country patents. Here, two issues are at work. The absence of patents in small developing countries is unimportant if those countries cannot import a low-cost generic version because of patent protection in countries that have the capacity to manufacture generics. In the African situation that Attaran discusses, patenting an antiretroviral in large markets such as South Africa may effectively remove incentive for generic manufacturers to produce and export to small African markets that do not have patent protection. The second issue is that when drugs are given the level of patent protection they enjoy in lucrative markets, they are priced so that a very high rate of return is guaranteed to manufacturers, and this conditions future expectations of return on investment. Even large developing countries may remain unattractive markets compared with North America, Europe, or Japan. More competition in developed markets and tighter margins-eg, by reduction of patent protection-could force large international manufacturers to cut their high costs and look at expansion of their markets in middle-income and lowincome countries.
We agree partly with Attaran's penultimate point: government interventions modify the patentee's theoretical ability to set prices. However, price controls are not solely used: the buying power of governmentsubsidised programmes-coupled with sensible use of reference-based price negotiations (or tendering)-provide some countries with prices that are much lower than in the free market of the USA.
Our response to Attaran's last point is that no one perspective can cover all dimensions of these complex issues. Patents are not the sole problem: the way they have been granted and used has led to the mess we are in. prescriptions by medical practitioners are irrational.
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Complementary and alternative medicine practitioners, who are untrained medically, prescribe allopathic medicines openly, and even prohibited drugs are available without prescription. 4 The problem is further compounded by the symbiosis that exists between qualified professionals and complementary and alternative medicine practitioners. Such practitioners refer difficult and serious patients to qualified allopathic private practitioners, and get tipped for the service.
Governments in developing countries must make more serious efforts to enforce the existing laws to improve health care, which presently looks elusive. We report a case of Cushing's syndrome in a 3-month-old infant due to irrational use of a steroid by a complementary and alternative medicine practioner. The infant was admitted to our hospital in September, 2001, with rapid breathing and chest indrawing. On physical examination she had cushingoid facies, truncal obesity, drumstick limbs, and paper-thin skin with striae. On enquiry, the mother showed us a small bottle of betamethasone, which was prescribed to the child at 15 days of life for upper respiratory tract infection. She had continued receiving this drug for the next 2 and a half months. We gave her ceftriaxone intravenously, and the steroid was gradually tapered off and stopped. The infant recovered and was discharged after 4 weeks in hospital. When last seen in August, 2002, there were no complaints.
Satish Agadi
Guidelines for over-the-counter steroids in developing countries are lacking.
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Kshirsagar and colleagues estimate that more than 30% of Secular trends in stroke mortality and early-life environment Sir-Debbie Lawlor and colleagues report that the decline of stroke in the 20th century was mainly attributable to the decline in mortality from haemorrhagic stroke (Dec 7, p 1818).
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This finding adds to evidence that the causes of haemorrhagic stroke are substantially different to the aetiological factors for ischaemic stroke and coronary heart disease.
We agree with Lawlor that early-life factors could account for this decline in deaths due to haemorrhagic stroke. However, they seem not to have considered the possibility that early-life blood pressure is one such factor. Perhaps this omission is wise, since publication of an extensive metaanalysis of usual blood pressure and vascular mortality, showing that agespecific associations with blood pressure are similar for strokes due to cerebral ischaemia and cerebral haemorrhage, 2 seems to rule out an explanatory role for blood pressure. However, the findings in this meta-analysis-as in most reports of blood pressure-stroke associationsrelied on blood pressure measured screens. The quality of the data displayed depends on the accurate matching of the laboratory data to Read codes selected by general practitioners. We became aware of serious errors in virology reports received by a Cambridgeshire general practitioner, and did a study to investigate the prevalence of these errors.
We extracted 1 month's virology and biochemistry laboratory reports from the pathology laboratory computer for 20 general practices chosen at random. We then visited these practices and cross-checked the data (name, date of birth, laboratory results) with those contained in the general practitioner's computer system.
There was a high rate of inaccurate virology results (mean 9%, range 0-54%), most of which were due to inaccurate matching of laboratory results with local Read codes. Examples of errors were anti-HBc laboratory results being matched with an HCV antibody Read code, and "influenza A antibody" being matched to "infant feeding advice". For biochemistry results, there was a smaller error rate (1%, 0-3%).
In all practices, there was a small error rate for spelling of names (4%, 0-8%) and date of birth (1%, 0-4%). 46% of these errors were the result of inaccurate data entry in the pathology laboratories, and 54% were due to incorrect completion of laboratory request forms by general practitioners or practice staff, or to illegible writing.
Practices that used four-bite codes found it more difficult to find suitable matches than those who had five-bite codes available. In practices that used four-bite codes, we were often unable to find suitable matching codes.
The errors in matching name and date of birth were not a serious problem, since by having one of these, the other could almost always be derived. However, errors such as assigning a patient who is positive for anti-HBc (indicating past resolved hepatitis B infection) to being positive for hepatitis C antibody has serious medical and sociological consequences.
This study has shown that when reports are transmitted electronically, robust audit procedures must be used to test the accuracy of the process. It also emphasises the value of involving pathologists in scrutinising the Read codes available for matching results. 
*Tim

Maintaining linguistic standards
Sir-Last year you published a Research letter by U Veronesi and colleagues 1 in which patients who had undergone hysterectomy were described as "hysterectomised women". This description was used again in subsequent Correspondence by J Benson (Nov 30, p 1784).
2 The word "hysterectomised" does not exist in the English language; moreover, the word "women" is superfluous since men cannot have a hysterectomy. The title should be "tamoxifen for breast cancer after a hysterectomy". As a prestigious English language medical journal you surely have a duty to maintain your linguistic standards.
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